<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">35508525</PMID><DateCompleted><Year>2022</Year><Month>05</Month><Day>06</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>27</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">2045-2322</ISSN><JournalIssue CitedMedium="Internet"><Volume>12</Volume><Issue>1</Issue><PubDate><Year>2022</Year><Month>May</Month><Day>04</Day></PubDate></JournalIssue><Title>Scientific reports</Title><ISOAbbreviation>Sci Rep</ISOAbbreviation></Journal><ArticleTitle>AAV9-mediated functional screening for cardioprotective cytokines in Coxsackievirus-B3-induced myocarditis.</ArticleTitle><Pagination><StartPage>7304</StartPage><MedlinePgn>7304</MedlinePgn></Pagination><ELocationID EIdType="pii" ValidYN="Y">7304</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1038/s41598-022-11131-w</ELocationID><Abstract><AbstractText>Viral myocarditis (VM) is an important cause of heart failure (HF) in children and adults. However, the molecular determinants involved in cardiac inflammation and cardiomyocyte necrosis remain poorly characterized, and cardioprotective molecules are currently missing. Here, we applied an in vivo method based on the functional selection (FunSel) of cardioprotective factors using AAV vectors for the unbiased identification of novel immunomodulatory molecules in a Coxsackievirus B3 (CVB3)-induced myocarditis mouse model. Two consecutive rounds of in vivo FunSel using an expression library of 60 cytokines were sufficient to identify five cardioprotective factors (IL9, IL3, IL4, IL13, IL15). The screening also revealed three cytokines (IL18, IL17b, and CCL11) that were counter-selected and likely to exert a detrimental effect. The pooled overexpression of the five most enriched cytokines using AAV9 vectors decreased inflammation and reduced cardiac dilatation, persisting at 1&#xa0;month after treatment. Individual overexpression of IL9, the top ranking in our functional selection, markedly reduced cardiac inflammation and injury, concomitant with an increase of anti-inflammatory Th2-cells and a reduction of pro-inflammatory Th17- and Th22-cells at 14&#xa0;days post-infection. AAV9-mediated FunSel cardiac screening identified IL9 and other four cytokines (IL3, IL4, IL13, and IL15) as cardioprotective factors in CVB3-induced VM in mice.</AbstractText><CopyrightInformation>&#xa9; 2022. The Author(s).</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Carai</LastName><ForeName>Paolo</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, Center for Vascular and Molecular Biology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CARIM, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruozi</LastName><ForeName>Giulia</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Paye</LastName><ForeName>Alexandra</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>CARIM, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Debing</LastName><ForeName>Yannick</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>CARIM, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Aligos Therapeutics, Leuven, Belgium.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bortolotti</LastName><ForeName>Francesca</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Lecomte</LastName><ForeName>Julie</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>CARIM, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zentilin</LastName><ForeName>Lorena</ForeName><Initials>L</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Jones</LastName><ForeName>Elizabeth A V</ForeName><Initials>EAV</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, Center for Vascular and Molecular Biology, KU Leuven, Leuven, Belgium.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CARIM, Maastricht University, Maastricht, The Netherlands.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giacca</LastName><ForeName>Mauro</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>International Centre for Genetic Engineering and Biotechnology (ICGEB), Trieste, Italy.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>King's College London, British Heart Foundation Centre of Research Excellence, School of Cardiovascular Medicine and Sciences, London, UK.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Heymans</LastName><ForeName>Stephane</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Department of Cardiovascular Sciences, Center for Vascular and Molecular Biology, KU Leuven, Leuven, Belgium. s.heymans@maastrichtuniversity.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>CARIM, Maastricht University, Maastricht, The Netherlands. s.heymans@maastrichtuniversity.nl.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Center for Heart Failure Research, CARIM, Department of Cardiology, Maastricht University Medical Center, PO BOX 5800, 6202 AZ, Maastricht, The Netherlands. s.heymans@maastrichtuniversity.nl.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2022</Year><Month>05</Month><Day>04</Day></ArticleDate></Article><MedlineJournalInfo><Country>England</Country><MedlineTA>Sci Rep</MedlineTA><NlmUniqueID>101563288</NlmUniqueID><ISSNLinking>2045-2322</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016207">Cytokines</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D018793">Interleukin-13</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019409">Interleukin-15</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D016906">Interleukin-9</NameOfSubstance></Chemical><Chemical><RegistryNumber>207137-56-2</RegistryNumber><NameOfSubstance UI="D015847">Interleukin-4</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D000818" MajorTopicYN="N">Animals</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D003384" MajorTopicYN="Y">Coxsackievirus Infections</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016207" MajorTopicYN="N">Cytokines</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="N">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D004195" MajorTopicYN="N">Disease Models, Animal</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D029822" MajorTopicYN="N">Enterovirus B, Human</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D007249" MajorTopicYN="N">Inflammation</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018793" MajorTopicYN="N">Interleukin-13</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019409" MajorTopicYN="N">Interleukin-15</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015847" MajorTopicYN="N">Interleukin-4</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D016906" MajorTopicYN="N">Interleukin-9</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D051379" MajorTopicYN="N">Mice</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008807" MajorTopicYN="N">Mice, Inbred BALB C</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D009205" MajorTopicYN="Y">Myocarditis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading></MeshHeadingList><CoiStatement>M.G. is a founder, consultant, and equity holder in Purespring Therapeutics (London, UK), which owns the rights on the FunSel technology and AAV library. F.B. is a consultant in the same company. All remaining authors, P.C., G.R., A.P., Y.D., J.L., L.Z., E.A.V.J., and S.H., declare no competing interests.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2021</Year><Month>10</Month><Day>1</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2022</Year><Month>3</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2022</Year><Month>5</Month><Day>4</Day><Hour>23</Hour><Minute>39</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2022</Year><Month>5</Month><Day>5</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2022</Year><Month>5</Month><Day>7</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2022</Year><Month>5</Month><Day>4</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">35508525</ArticleId><ArticleId IdType="pmc">PMC9067557</ArticleId><ArticleId IdType="doi">10.1038/s41598-022-11131-w</ArticleId><ArticleId IdType="pii">10.1038/s41598-022-11131-w</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Pollack A, Kontorovich AR, Fuster V, Dec GW. Viral myocarditis&#x2014;Diagnosis, treatment options and current controversies. Nat. Rev. Cardiol. 2015;12:670&#x2013;680. doi: 10.1038/nrcardio.2015.108.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nrcardio.2015.108</ArticleId><ArticleId IdType="pubmed">26194549</ArticleId></ArticleIdList></Reference><Reference><Citation>Ponikowski P, et al. 2016 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur. Heart J. 2016;37:2129&#x2013;2200m. doi: 10.1093/eurheartj/ehw128.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/eurheartj/ehw128</ArticleId><ArticleId IdType="pubmed">28402409</ArticleId></ArticleIdList></Reference><Reference><Citation>Tsch&#xf6;pe C, Cooper LT, Torre-Amione G, van Linthout S. Management of myocarditis-related cardiomyopathy in adults. Circ. Res. 2019;124:1568&#x2013;1583. doi: 10.1161/CIRCRESAHA.118.313578.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.118.313578</ArticleId><ArticleId IdType="pubmed">31120823</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu PP, Blet A, Smyth D, Li H. The Science underlying COVID-19: Implications for the cardiovascular system. Circulation. 2020;142:68&#x2013;78. doi: 10.1161/CIRCULATIONAHA.120.047549.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.120.047549</ArticleId><ArticleId IdType="pubmed">32293910</ArticleId></ArticleIdList></Reference><Reference><Citation>Adamo L, Rocha-Resende C, Prabhu SD, Mann DL. Reappraising the role of inflammation in heart failure. Nat. Rev. Cardiol. 2020;17:269&#x2013;285. doi: 10.1038/s41569-019-0315-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41569-019-0315-x</ArticleId><ArticleId IdType="pubmed">31969688</ArticleId></ArticleIdList></Reference><Reference><Citation>Hang W, Chen C, Seubert JM, Wang DW. Fulminant myocarditis: A comprehensive review from etiology to treatments and outcomes. Signal Transduct. Target. Ther. 2020;5:287. doi: 10.1038/s41392-020-00360-y.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41392-020-00360-y</ArticleId><ArticleId IdType="pmc">PMC7730152</ArticleId><ArticleId IdType="pubmed">33303763</ArticleId></ArticleIdList></Reference><Reference><Citation>Altan-Bonnet G, Mukherjee R. Cytokine-mediated communication: A quantitative appraisal of immune complexity. Nat. Rev. Immunol. 2019;19:205&#x2013;217. doi: 10.1038/s41577-019-0131-x.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41577-019-0131-x</ArticleId><ArticleId IdType="pmc">PMC8126146</ArticleId><ArticleId IdType="pubmed">30770905</ArticleId></ArticleIdList></Reference><Reference><Citation>Ruozi G, et al. AAV-mediated in vivo functional selection of tissue-protective factors against ischaemia. Nat. Commun. 2015;6:7388. doi: 10.1038/ncomms8388.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/ncomms8388</ArticleId><ArticleId IdType="pmc">PMC4477044</ArticleId><ArticleId IdType="pubmed">26066847</ArticleId></ArticleIdList></Reference><Reference><Citation>Zincarelli C, Soltys S, Rengo G, Rabinowitz JE. Analysis of AAV serotypes 1&#x2013;9 mediated gene expression and tropism in mice after systemic injection. Mol. Ther. 2008;16:1073&#x2013;1080. doi: 10.1038/mt.2008.76.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/mt.2008.76</ArticleId><ArticleId IdType="pubmed">18414476</ArticleId></ArticleIdList></Reference><Reference><Citation>Zweifel M, Matozan K, Dahinden C, Schaffner T, Mohacsi P. Eotaxin/CCL11 levels correlate with myocardial fibrosis and mast cell density in native and transplanted rat hearts. Transpl. Proc. 2010;42:2763&#x2013;2766. doi: 10.1016/j.transproceed.2010.05.152.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.transproceed.2010.05.152</ArticleId><ArticleId IdType="pubmed">20832583</ArticleId></ArticleIdList></Reference><Reference><Citation>Westermann D, et al. Reduced degradation of the chemokine MCP-3 by matrix metalloproteinase-2 exacerbates myocardial inflammation in experimental viral cardiomyopathy. Circulation. 2011;124:2082&#x2013;2093. doi: 10.1161/CIRCULATIONAHA.111.035964.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.111.035964</ArticleId><ArticleId IdType="pubmed">21986287</ArticleId></ArticleIdList></Reference><Reference><Citation>Diny NL, et al. Macrophages and cardiac fibroblasts are the main producers of eotaxins and regulate eosinophil trafficking to the heart. Eur. J. Immunol. 2016;46:2749&#x2013;2760. doi: 10.1002/eji.201646557.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/eji.201646557</ArticleId><ArticleId IdType="pmc">PMC5404278</ArticleId><ArticleId IdType="pubmed">27621211</ArticleId></ArticleIdList></Reference><Reference><Citation>Myers, J. M. et al. Cardiac myosin-Th17 responses promote heart failure in human myocarditis. JCI Insight1 (2016).</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4924810</ArticleId><ArticleId IdType="pubmed">27366791</ArticleId></ArticleIdList></Reference><Reference><Citation>Hoffmann J, et al. Circulating Th17 and Th22 cells are associated with CMR imaging biosignatures of diffuse myocardial interstitial remodeling in chronic coronary artery disease. Circ. Res. 2020;127:699&#x2013;701. doi: 10.1161/CIRCRESAHA.120.316619.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCRESAHA.120.316619</ArticleId><ArticleId IdType="pmc">PMC7418928</ArticleId><ArticleId IdType="pubmed">32576092</ArticleId></ArticleIdList></Reference><Reference><Citation>Bortolotti F, et al. In vivo functional selection identifies cardiotrophin-1 as a cardiac engraftment factor for mesenchymal stromal cells. Circulation. 2017;136:1509&#x2013;1524. doi: 10.1161/CIRCULATIONAHA.117.029003.</Citation><ArticleIdList><ArticleId IdType="doi">10.1161/CIRCULATIONAHA.117.029003</ArticleId><ArticleId IdType="pubmed">28754835</ArticleId></ArticleIdList></Reference><Reference><Citation>Rauber S, et al. Resolution of inflammation by interleukin-9-producing type 2 innate lymphoid cells. Nat. Med. 2017;23:938. doi: 10.1038/nm.4373.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nm.4373</ArticleId><ArticleId IdType="pmc">PMC5575995</ArticleId><ArticleId IdType="pubmed">28714991</ArticleId></ArticleIdList></Reference><Reference><Citation>Lu L-F, et al. Mast cells are essential intermediaries in regulatory T-cell tolerance. Nature. 2006 doi: 10.1038/nature05010.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nature05010</ArticleId><ArticleId IdType="pubmed">16921386</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu M, et al. IL-9 inhibits viral replication in coxsackievirus B3-induced myocarditis. Front. Immunol. 2016;7:409.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5052262</ArticleId><ArticleId IdType="pubmed">27766098</ArticleId></ArticleIdList></Reference><Reference><Citation>Abston ED, et al. Th2 regulation of viral myocarditis in mice: Different roles for TLR3 versus TRIF in progression to chronic disease. Clin. Dev. Immunol. 2012;2012:1&#x2013;12. doi: 10.1155/2012/129486.</Citation><ArticleIdList><ArticleId IdType="doi">10.1155/2012/129486</ArticleId><ArticleId IdType="pmc">PMC3195533</ArticleId><ArticleId IdType="pubmed">22013485</ArticleId></ArticleIdList></Reference><Reference><Citation>Huber SA, Pfaeffle B. Differential Th1 and Th2 cell responses in male and female BALB/c mice infected with coxsackievirus group B type 3. J. Virol. 1994;68:5126&#x2013;5132. doi: 10.1128/jvi.68.8.5126-5132.1994.</Citation><ArticleIdList><ArticleId IdType="doi">10.1128/jvi.68.8.5126-5132.1994</ArticleId><ArticleId IdType="pmc">PMC236456</ArticleId><ArticleId IdType="pubmed">8035512</ArticleId></ArticleIdList></Reference><Reference><Citation>Frisancho-Kiss S, et al. Gonadectomy of male BALB/c mice increases Tim-3+ alternatively activated M2 macrophages, Tim-3+ T cells, Th2 cells and Treg in the heart during acute coxsackievirus-induced myocarditis. Brain Behav. Immun. 2009;23:649&#x2013;657. doi: 10.1016/j.bbi.2008.12.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.bbi.2008.12.002</ArticleId><ArticleId IdType="pmc">PMC3148833</ArticleId><ArticleId IdType="pubmed">19126426</ArticleId></ArticleIdList></Reference><Reference><Citation>Jin H, Guo X. Valproic acid ameliorates coxsackievirus-B3-induced viral myocarditis by modulating Th17/Treg imbalance. Virol. J. 2016;13:168. doi: 10.1186/s12985-016-0626-z.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/s12985-016-0626-z</ArticleId><ArticleId IdType="pmc">PMC5057454</ArticleId><ArticleId IdType="pubmed">27724948</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang Y, Xu C, Tang S, Xia Z. Interleukin-9 aggravates isoproterenol-induced heart failure by activating signal transducer and activator of transcription 3 signalling. Can. J. Cardiol. 2020;36:1770&#x2013;1781. doi: 10.1016/j.cjca.2020.01.011.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.cjca.2020.01.011</ArticleId><ArticleId IdType="pubmed">32621886</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhan T, et al. Interleukin-9 blockage reduces early hepatic granuloma formation and fibrosis during Schistosomajaponicum infection in mice. Immunology. 2019;158:296&#x2013;303. doi: 10.1111/imm.13111.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/imm.13111</ArticleId><ArticleId IdType="pmc">PMC6856936</ArticleId><ArticleId IdType="pubmed">31436861</ArticleId></ArticleIdList></Reference><Reference><Citation>Sugimoto N, et al. IL-9 blockade suppresses silica-induced lung inflammation and fibrosis in mice. Am. J. Respir. Cell Mol. Biol. 2019;60:232&#x2013;243. doi: 10.1165/rcmb.2017-0287OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2017-0287OC</ArticleId><ArticleId IdType="pubmed">30240278</ArticleId></ArticleIdList></Reference><Reference><Citation>Zhao Y-B, et al. Interaction between regulatory T cells and mast cells via IL-9 and TGF-beta; production. Oncol. Lett. 2020;20:1&#x2013;1.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC7590434</ArticleId><ArticleId IdType="pubmed">33133260</ArticleId></ArticleIdList></Reference><Reference><Citation>van den Br&#xfb;le S, et al. Profibrotic effect of IL-9 overexpression in a model of airway remodeling. Am. J. Respir. Cell Mol. Biol. 2007;37:202&#x2013;209. doi: 10.1165/rcmb.2006-0397OC.</Citation><ArticleIdList><ArticleId IdType="doi">10.1165/rcmb.2006-0397OC</ArticleId><ArticleId IdType="pubmed">17446528</ArticleId></ArticleIdList></Reference><Reference><Citation>Srivastava RK, et al. IL-3 attenuates collagen-induced arthritis by modulating the development of Foxp3 + regulatory T cells. J. Immunol. 2011;186:2262&#x2013;2272. doi: 10.4049/jimmunol.1002691.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1002691</ArticleId><ArticleId IdType="pubmed">21242512</ArticleId></ArticleIdList></Reference><Reference><Citation>Kumar A, et al. IL-3 receptor expression on activated human Th cells is regulated by IL-4, and IL-3 synergizes with IL-4 to enhance Th2 cell differentiation. J. Immunol. 2020;204:819&#x2013;831. doi: 10.4049/jimmunol.1801629.</Citation><ArticleIdList><ArticleId IdType="doi">10.4049/jimmunol.1801629</ArticleId><ArticleId IdType="pubmed">31900339</ArticleId></ArticleIdList></Reference><Reference><Citation>Jiang ZJ, et al. Remission of CVB3-induced viral myocarditis by in vivo Th2 polarization via hydrodynamics-based interleukin-4 gene transfer. J. Gene Med. 2008;10:918&#x2013;929. doi: 10.1002/jgm.1215.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/jgm.1215</ArticleId><ArticleId IdType="pubmed">18512734</ArticleId></ArticleIdList></Reference><Reference><Citation>Wan F, et al. V&#x3b3;1+&#x3b3;&#x3b4;T, early cardiac infiltrated innate population dominantly producing IL-4, protect mice against CVB3 myocarditis by modulating IFN&#x3b3;+ T response. Mol. Immunol. 2017;81:16&#x2013;25. doi: 10.1016/j.molimm.2016.11.006.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.molimm.2016.11.006</ArticleId><ArticleId IdType="pubmed">27886550</ArticleId></ArticleIdList></Reference><Reference><Citation>Liu L, Yue Y, Xiong S. NK-derived IFN-&#x3b3;/IL-4 triggers the sexually disparate polarization of macrophages in CVB3-induced myocarditis. Curr. Ther. Res. Clin. Exp. 2014;76:15&#x2013;25.</Citation><ArticleIdList><ArticleId IdType="pubmed">25123338</ArticleId></ArticleIdList></Reference><Reference><Citation>Yang H, Chen Y, Gao C. Interleukin-13 reduces cardiac injury and prevents heart dysfunction in viral myocarditis via enhanced M2 macrophage polarization. Oncotarget. 2017;8:99495&#x2013;99503. doi: 10.18632/oncotarget.20111.</Citation><ArticleIdList><ArticleId IdType="doi">10.18632/oncotarget.20111</ArticleId><ArticleId IdType="pmc">PMC5725109</ArticleId><ArticleId IdType="pubmed">29245918</ArticleId></ArticleIdList></Reference><Reference><Citation>Cihakova D, et al. Interleukin-13 protects against experimental autoimmune myocarditis by regulating macrophage differentiation. Am. J. Pathol. 2008;172:1195&#x2013;1208. doi: 10.2353/ajpath.2008.070207.</Citation><ArticleIdList><ArticleId IdType="doi">10.2353/ajpath.2008.070207</ArticleId><ArticleId IdType="pmc">PMC2329830</ArticleId><ArticleId IdType="pubmed">18403598</ArticleId></ArticleIdList></Reference><Reference><Citation>Yeghiazarians Y, et al. IL-15: A novel prosurvival signaling pathway in cardiomyocytes. J. Cardiovasc. Pharmacol. 2014;63:406&#x2013;411. doi: 10.1097/FJC.0000000000000061.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/FJC.0000000000000061</ArticleId><ArticleId IdType="pmc">PMC4115639</ArticleId><ArticleId IdType="pubmed">24805144</ArticleId></ArticleIdList></Reference><Reference><Citation>Bigalke B, Schwimmbeck PL, Haas CS, Lindemann S. Effect of interleukin-15 on the course of myocarditis in Coxsackievirus B3-infected BALB/c mice. Can. J. Cardiol. 2009;25:e248&#x2013;e254. doi: 10.1016/S0828-282X(09)70511-2.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/S0828-282X(09)70511-2</ArticleId><ArticleId IdType="pmc">PMC2723035</ArticleId><ArticleId IdType="pubmed">19584981</ArticleId></ArticleIdList></Reference><Reference><Citation>Shi Y, et al. A novel cytokine receptor-ligand pair: Identification, molecular characterization, and in vivo immunomodutory activity. J. Biol. Chem. 2000;275:19167&#x2013;19176. doi: 10.1074/jbc.M910228199.</Citation><ArticleIdList><ArticleId IdType="doi">10.1074/jbc.M910228199</ArticleId><ArticleId IdType="pubmed">10749887</ArticleId></ArticleIdList></Reference><Reference><Citation>Yu Q, et al. IL-18 induction of osteopontin mediates cardiac fibrosis and diastolic dysfunction in mice. Am. J. Physiol. Heart Circ. Physiol. 2009;297:H76&#x2013;H85. doi: 10.1152/ajpheart.01285.2008.</Citation><ArticleIdList><ArticleId IdType="doi">10.1152/ajpheart.01285.2008</ArticleId><ArticleId IdType="pmc">PMC2711747</ArticleId><ArticleId IdType="pubmed">19429811</ArticleId></ArticleIdList></Reference><Reference><Citation>Kanda T, et al. Effect of interleukin-18 on viral myocarditis: Enhancement of interferon-&#x3b3; and natural killer cell activity. J. Mol. Cell. Cardiol. 2000;32:2163&#x2013;2171. doi: 10.1006/jmcc.2000.1242.</Citation><ArticleIdList><ArticleId IdType="doi">10.1006/jmcc.2000.1242</ArticleId><ArticleId IdType="pubmed">11112992</ArticleId></ArticleIdList></Reference><Reference><Citation>Esper L, et al. Regulatory effects of IL-18 on cytokine profiles and development of myocarditis during Trypanosomacruzi infection. Microbes Infect. 2014;16:481&#x2013;490. doi: 10.1016/j.micinf.2014.03.007.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.micinf.2014.03.007</ArticleId><ArticleId IdType="pubmed">24704475</ArticleId></ArticleIdList></Reference><Reference><Citation>Dagan A, Langevitz P, Shoenfeld Y, Shovman O. Anakinra in idiopathic recurrent pericarditis refractory to immunosuppressive therapy; A preliminary experience in seven patients. Autoimmun. Rev. 2019;18:627&#x2013;631. doi: 10.1016/j.autrev.2019.01.005.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.autrev.2019.01.005</ArticleId><ArticleId IdType="pubmed">30959216</ArticleId></ArticleIdList></Reference><Reference><Citation>Cavalli G, et al. Interleukin-1 receptor blockade rescues myocarditis-associated end-stage heart failure. Front. Immunol. 2017;8:131. doi: 10.3389/fimmu.2017.00131.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2017.00131</ArticleId><ArticleId IdType="pmc">PMC5298961</ArticleId><ArticleId IdType="pubmed">28232838</ArticleId></ArticleIdList></Reference><Reference><Citation>Jackson LA, et al. An mRNA vaccine against SARS-CoV-2&#x2014;Preliminary report. N. Engl. J. Med. 2020;383:1920&#x2013;1931. doi: 10.1056/NEJMoa2022483.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2022483</ArticleId><ArticleId IdType="pmc">PMC7377258</ArticleId><ArticleId IdType="pubmed">32663912</ArticleId></ArticleIdList></Reference><Reference><Citation>Polack FP, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 2020;383:2603&#x2013;2615. doi: 10.1056/NEJMoa2034577.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2034577</ArticleId><ArticleId IdType="pmc">PMC7745181</ArticleId><ArticleId IdType="pubmed">33301246</ArticleId></ArticleIdList></Reference><Reference><Citation>Faul F, Erdfelder E, Buchner A, Lang A-G. Statistical power analyses using G*Power 3.1: Tests for correlation and regression analyses. Behav. Res. Methods. 2009;41:1149&#x2013;1160. doi: 10.3758/BRM.41.4.1149.</Citation><ArticleIdList><ArticleId IdType="doi">10.3758/BRM.41.4.1149</ArticleId><ArticleId IdType="pubmed">19897823</ArticleId></ArticleIdList></Reference><Reference><Citation>Rienks M, et al. A novel 72-kDa leukocyte-derived osteoglycin enhances the activation of toll-like receptor 4 and exacerbates cardiac inflammation during viral myocarditis. Cell. Mol. Life Sci. 2017;74:1511&#x2013;1525. doi: 10.1007/s00018-016-2423-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1007/s00018-016-2423-7</ArticleId><ArticleId IdType="pmc">PMC5357299</ArticleId><ArticleId IdType="pubmed">27878326</ArticleId></ArticleIdList></Reference><Reference><Citation>Schindelin J, et al. Fiji: An open-source platform for biological-image analysis. Nat. Methods. 2012;9:676&#x2013;682. doi: 10.1038/nmeth.2019.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/nmeth.2019</ArticleId><ArticleId IdType="pmc">PMC3855844</ArticleId><ArticleId IdType="pubmed">22743772</ArticleId></ArticleIdList></Reference><Reference><Citation>Deckx S, et al. Osteoglycin prevents the development of age-related diastolic dysfunction during pressure overload by reducing cardiac fibrosis and inflammation. Matrix Biol. 2017;66:110&#x2013;124. doi: 10.1016/j.matbio.2017.09.002.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.matbio.2017.09.002</ArticleId><ArticleId IdType="pubmed">28958774</ArticleId></ArticleIdList></Reference><Reference><Citation>Cuijpers I, et al. The effect of different anaesthetics on echocardiographic evaluation of diastolic dysfunction in a heart failure with preserved ejection fraction model. Sci. Rep. 2020;10:15701. doi: 10.1038/s41598-020-72924-5.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41598-020-72924-5</ArticleId><ArticleId IdType="pmc">PMC7518268</ArticleId><ArticleId IdType="pubmed">32973263</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>